First Trust Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

First Trust Advisors’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-26,813	Closed	-$846K	–	2498
2022 Q4	$846K	Sell	26,813 -32,121	-55%	-$906K	﹤0.01%	2014
2022 Q3	$1.67M	Buy	58,934 +22,175	+60%	+$660K	﹤0.01%	1773
2022 Q2	$972K	Sell	36,759 -57,993	-61%	-$1.65M	﹤0.01%	1999
2022 Q1	$3.32M	Sell	94,752 -12,274	-11%	-$358K	﹤0.01%	1560
2021 Q4	$3.47M	Buy	107,026 +55,029	+106%	+$1.94M	﹤0.01%	1561
2021 Q3	$1.53M	Buy	+51,997	New	+$1.46M	﹤0.01%	1873

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

First Trust Advisors's CERE Position: Q1 2023 in Review

First Trust Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2023, closing a stake of 26,813 shares — an estimated $846K sold.

First Trust Advisors first reported a position in CERE in Q3 2021 and held it in 6 quarters. The position peaked at $3.47M in Q4 2021. 119 funds tracked by Wall St. Rank hold CERE as of Q1 2023.

First Trust Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
First Trust Advisors sold 26,813 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2023, an estimated $846K.
First Trust Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
First Trust Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.47M in Q4 2021.
119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2023.

Based on First Trust Advisors's 13F filing for Q1 2023, filed 15 May 2023.